Characterization of NiCas12b for In Vivo Genome Editing
Advanced Science · 2024
DOI: 10.1002/advs.202400469 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Yunqian Zhang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, State Key Laboratory of Genetic Engineer…. Hauptthemen laut MEDLINE: Gene Editing, CRISPR-Cas Systems. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 51 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Science and Technology Research Program of Shanghai.
Abstract (Originalsprache)
The RNA‐guided clustered regularly interspaced short palindromic repeats (CRISPR)/Cas12b system represents the third family of CRISPR‐Cas systems that are harnessed for genome editing. However, only a few nucleases have demonstrated activity in human cells, and their in vivo therapeutic potential remains uncertain. In this study, a green fluorescent protein (GFP)‐activation assay is conducted to screen a panel of 15 Cas12b orthologs, and four of them exhibited editing activity in mammalian cells. Particularly noteworthy is the NiCas12b derived from Nitrospira sp ., which recognizes a “TTN” protospacer adjacent motif (PAM) and facilitates efficient genome editing in various cell lines. Importantly, NiCas12b also exhibits a high degree of specificity, rendering it suitable for therapeutic applications. As proof of concept, the adeno‐associated virus (AAV) is employed to introduce NiCas12b to target the cholesterol regulatory gene proprotein convertase subtilisin/ kexin type 9 ( Pcsk9 ) in the mouse liver. After 4 weeks of injections, an impressive is observed over 16.0% insertion/deletion (indel) efficiency, resulting in a significant reduction in serum cholesterol levels. NiCas12b provides a novel option for both basic research and clinical applications.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, State Key Laboratory of Genetic Engineering at School of Life Sciences, Fudan University, Shanghai, 200438, Ch…
- Center for Medical Research and Innovation, Shanghai Pudong Hospital, Fudan University Pudong Medical Center, Fudan University, Shanghai, 200438, China.
- Obstetrics & Gynecology Hospital, State Key Laboratory of Genetic Engineering, Shanghai Key Laboratory of Metabolic Remodeling and Health, Institute of Metabolism and Integrative Biology, Fudan University, Shanghai, 200…
- Children's Hospital, Fudan University, Shanghai, 201102, China.
- Shanghai Engineering Research Center of Industrial Microorganisms, Shanghai, 200438, China.
ORCID-Profile: Yunqian Zhang, Hongyan Wang, Yongming Wang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
- Science and Technology Research Program of Shanghai
Zitieren
APA
Zhang, Y., Wei, J., Wang, H., & Wang, Y. (2024). Characterization of NiCas12b for In Vivo Genome Editing. Advanced Science. https://doi.org/10.1002/advs.202400469
Vancouver
Zhang Y, Wei J, Wang H, Wang Y. Characterization of NiCas12b for In Vivo Genome Editing. Advanced Science. 2024. doi:10.1002/advs.202400469
BibTeX
@article{Zhang2024,
author = {Zhang, Yunqian and Wei, Jingjing and Wang, Hongyan and Wang, Yongming},
title = {Characterization of NiCas12b for In Vivo Genome Editing},
journal = {Advanced Science},
year = {2024},
doi = {10.1002/advs.202400469}
}
EUVIMED